VK2735 Shows Up to 14.7% Weight Loss in Phase 2, No Plateau Observed—Phase 3 Now Underway

Significant Weight Loss Demonstrated: VK2735 Achieves Up to 14.7% Reduction After 13 Weeks

Viking Therapeutics has released peer-reviewed data in the journal Obesity from its Phase 2 VENTURE trial of VK2735, a dual GLP-1/GIP receptor agonist. The study found participants receiving VK2735 saw reductions in mean body weight from baseline of up to 14.7% after just 13 weeks of weekly subcutaneous injections. Importantly, the results showed no evidence of a plateau in weight loss during this period, suggesting the therapy’s effect may continue with prolonged use.

Tolerability and Safety Profile Remain Encouraging

Beyond its weight reduction effect, VK2735 demonstrated an encouraging safety and tolerability profile in the VENTURE study. The majority of adverse events were rated either mild or moderate, with discontinuation rates in VK2735 arms well-balanced versus placebo. This favorable safety data further supports VK2735’s continued clinical evaluation.

Phase 3 VANQUISH Trials Aim to Confirm Promise Seen in Phase 2

Viking is now advancing VK2735 into two major Phase 3 studies—VANQUISH-1 and VANQUISH-2—designed to test efficacy and safety over a longer 78-week period. VANQUISH-1 has enrolled about 4,650 adults with obesity or overweight and at least one weight-related co-morbidity, while VANQUISH-2 is focusing on approximately 1,100 adults with type 2 diabetes and obesity or overweight. In both studies, patients are randomized to receive either one of three VK2735 doses or placebo.

Potential for Best-in-Class Dual Agonist Therapeutics

The Phase 2 data positions VK2735 as a potential best-in-class agent among dual GLP-1/GIP agonists, challenging existing products like tirzepatide by delivering compelling weight loss and robust safety. GLP-1 receptor agonists—already known for decreasing glucose, reducing appetite, and aiding in weight loss—are further empowered by dual GIP activation, as emerging data continue to validate. VK2735’s ongoing late-stage trials and recently completed maintenance dosing study may help define its future role for obesity and metabolic disorder treatment.

What to Watch For: Upcoming Results and Market Impact

Investors and the medical community will want to track updates from the VANQUISH-1 and VANQUISH-2 programs. Success in Phase 3 could set VK2735 apart as a leading contender in the obesity treatment landscape, especially given the high bar set by competing dual agonists already approved by the FDA. With the VANQUISH-2 trial expected to complete enrollment in early 2026, and the maintenance study recently finished, attention will focus on long-term efficacy, safety, and comparison to established therapies.

While promising, further data will be crucial to determine just how far VK2735 can move the needle in addressing the global obesity epidemic.

Contact Information:

If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.

About the Publisher - Marketchameleon.com:

Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.

NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.

The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.

Disclosure: This article was generated with the assistance of AI